Novo Nordisk has signed a deal with AI-driven protein design company Gensaic to develop tissue-targeted therapies for ...

Revvity, Inc. , today announced the launch of EUROIMMUN's CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status against ...

A national survey conducted by MedStar Health to gauge the public's knowledge of screening guidelines for colorectal cancer, ...

Gensaic partnership with Novo Nordisk, worth up to $354M, aims to develop next-generation precision therapies using novel protein design technology.

Novo is paying Gensaic up to $354 million per target in upfront fees and development and commercial milestones, plus tiered ...